Sacituzumab Govitecan Yields Consistent Benefit in Platinum-Ineligible mUC
February 18th 2023Data from the phase 2 TROPHY-U-01 trial support further evaluation of sacituzumab govitecan in patients with metastatic urothelial cancer following immune checkpoint inhibitor therapy, according to the lead investigator.
Niraparib Combination Continues to Improve Outcomes in Metastatic CRPC
February 17th 2023Niraparib plus abiraterone and prednisone continue to improve outcomes among patients with metastatic, castration-resistant prostate cancer and HRR gene alterations, according to interim data from the MAGNITUDE study.
Darolutamide Demonstrates Long-Term Safety in Nonmetastatic CRPC
February 17th 2023Long-term safety data from the phase 3 ARAMIS rollover trial support the use of darolutamide in patients with nonmetastatic castration-resistant prostate cancer, according to an expert from the Carolina Urologic Research Center.
Abiraterone Combo Shows Sustained OS Benefit in Prostate Cancer Subtype
February 17th 2023In a final overall survival analysis of the phase 3 PROpel study, abiraterone actetate/olaparib demonstrates a sustained trend toward overall survival for metastatic castration-resistant prostate cancer vs standard-of-care abiraterone.
Frontline Talazoparib/Enzalutamide Garners rPFS Benefit vs Placebo in mCRPC
February 17th 2023Treatment with talazoparib and enzalutamide appears to yield a statistically significant and clinically meaningful radiographic progression-free survival benefit compared with placebo/enzalutamide in frontline metastatic castration-resistant prostate cancer regardless of homologous recombination repair status.
Sequencing Radioligands Appears to be Safe, Viable Strategy for mCRPC
February 16th 2023Treatment with 177Lu-PSMA-617 results in similar survival benefit regardless of when it was administered after radium-223 in patients with metastatic castration-resistant prostate cancer, according to an expert from University Hospital of Münster in Germany.
Ponatinib Combo Demonstrates Superiority Vs Imatinib in Ph+ Leukemia Subtype
February 16th 2023An expert from the University of Texas MD Anderson Cancer Center says that ponatinib plus reduced-intensity chemotherapy may be a new standard of care for frontline Philadelphia chromosome–positive acute lymphoblastic leukemia.
NCCN Guidelines Update Includes Injection for Cisplatin Ototoxicity in AYAs
February 14th 2023A medical oncologist and research audiologist from St. Jude Children’s Research Hospital discuss how sodium thiosulfate injection may improve quality of life by preventing cisplatin-associated ototoxicities in pediatric patients with localized non-metastatic tumors, although more research is needed.
Momelotinib May Set New Standard in Myelofibrosis, Expert Says
February 14th 2023“Transfusion independence is the key to my excitement [with] momelotinib as a drug. I will likely use it in most patients in the second-line setting,” says an expert from the University of Texas MD Anderson Cancer Center.
Trilaciclib Reduces Neutropenia but Fails to Improve ORR in Metastatic CRC
February 13th 2023Although trilaciclib appears to reduce neutropenia following treatment with FOLFOXIRI and bevacizumab in patients with metastatic colorectal cancer, the phase 3 PRESERVE 1 trial will be stopped due to a lack of responses.